Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals

Jiang, Si-Liang; Fu, Yu; Zhang, Xinyang; Yu, Tong; Lu, Bowen; Du, Jianxiu

doi:10.3389/fbioe.2021.799806

Cited by 12 publications

(5 citation statements)

References 71 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is about to begin Phyto molecules are easily defused through the cell membrane, intracellular organs and induce oxidative stress. Nanoparticles-based Phyto molecules have transformed the HRE2+ BC therapy significantly improving clinical outcome ( Jiang et al, 2021 ). All these approaches have shown significant outcomes and reduced the tumour microenvironment burden.…”

Section: Nanotechnology To Treat Her2-positive Bcmentioning

confidence: 99%

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer

2022

View full text Add to dashboard Cite

Breast cancer (BC) is caused by epigenetic modifications and genetic heterogeneity and exhibits various histological feature. HER2+ (Human epidermal growth factor receptor 2) is a more aggressive type of breast cancer, diagnosis and prognosis are difficult for HER2+ BC. Anti-HER2+ inhibitors have been effectively used for patient treatment. High mortality rate is reported in HER2+ BC, due to availability of limited therapeutic options. Despite advances in systemic medications to treat metastatic breast cancer (MBC), HER2-positive MBC is still challenging for patients and treating clinicians. The clinical characteristics of the disease have changed after treatment with HER2-targeted therapy. Various types of Tyrosine kinase inhibitors (TKIs) have been developed to treat patients with HER2+ BC including afatinib, lapatinib, neratinib, tucatinib, and pyrotinib, have been developed as HER2-targeted therapies. The antibody-drug conjugates adotrastuzumab, emtansine, famtrastuzumab, and deruxtecan, as well as the anti-HER2 monoclonal antibody pertuzumab are used in both early-stage and metastatic situations, either alone or in conjunction with chemotherapy and other HER2-targeting therapies. The emergence of drug resistance in anti-HER2 therapies has been observed. To overcome drug resistance and limited efficacy in current treatment options, nano formulations can be used in patients with HER2+ BC treatment. Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors.

show abstract

Section: Nanotechnology To Treat Her2-positive Bcmentioning

confidence: 99%

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer

2022

View full text Add to dashboard Cite

show abstract

“…In addition to the aforementioned groups of phytochemicals, additional plant-derived anticancer drugs such as combretastatins, homoharringtonine (omacetaxine mepesuccinate, cephalotaxine alkaloid), and ingenol mebutate are also used ( Table 1 ). Research has concentrated on finding ways to eliminate the consequences of the phytochemicals poor water solubility and its considerable hazardous side effects [ 82 ]. Several attempts have been made to improve water solubility and tumor selectivity, leading to the synthesis of numerous analogs and prodrugs in this area [ 83 ].…”

Section: Mechanisms Of Cancer Chemopreventionmentioning

confidence: 99%

Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation

Ahmed

Islam

Alghamdi

et al. 2022

IJMS

View full text Add to dashboard Cite

Cancer is one of the deadliest non communicable diseases. Numerous anticancer medications have been developed to target the molecular pathways driving cancer. However, there has been no discernible increase in the overall survival rate in cancer patients. Therefore, innovative chemo-preventive techniques and agents are required to supplement standard cancer treatments and boost their efficacy. Fruits and vegetables should be tapped into as a source of compounds that can serve as cancer therapy. Phytochemicals play an important role as sources of new medication in cancer treatment. Some synthetic and natural chemicals are effective for cancer chemoprevention, i.e., the use of exogenous medicine to inhibit or impede tumor development. They help regulate molecular pathways linked to the development and spread of cancer. They can enhance antioxidant status, inactivating carcinogens, suppressing proliferation, inducing cell cycle arrest and death, and regulating the immune system. While focusing on four main categories of plant-based anticancer agents, i.e., epipodophyllotoxin, camptothecin derivatives, taxane diterpenoids, and vinca alkaloids and their mode of action, we review the anticancer effects of phytochemicals, like quercetin, curcumin, piperine, epigallocatechin gallate (EGCG), and gingerol. We examine the different signaling pathways associated with cancer and how inflammation as a key mechanism is linked to cancer growth.

show abstract

“…20,21 The construction of carrier-free SANDDSs based on the self-assembly characteristics of NSMs in particular can greatly improve the drug curative effects by conferring greater tissue targeting and water solubility than traditional synthetic anti-cancer drugs. 22 Recently, Xie and colleagues reviewed the self-assembly mechanisms of TCM-derived NSMs and the clinical potential of these NSMs for the treatment of cancers and neurological diseases. They concluded that further research on the selfassembly of NSMs will accelerate the development of these compounds for clinical treatment.…”

Section: Introductionmentioning

confidence: 99%